Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder pain.
<h4>Background</h4>Activation of intravesical protease activated receptor 4 (PAR4) leads to release of urothelial macrophage migration inhibitory factor (MIF). MIF then binds to urothelial MIF receptors to release urothelial high mobility group box-1 (HMGB1) and elicit bladder hyperalges...
Guardado en:
Autores principales: | Shaojing Ye, Fei Ma, Dlovan F D Mahmood, Katherine L Meyer-Siegler, Raymond E Menard, David E Hunt, Lin Leng, Richard Bucala, Pedro L Vera |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7fc27f72d7f44943824ab56be9a0a3f1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies
por: Jin X, et al.
Publicado: (2016) -
Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis
por: Hirohito Kanemitsu, et al.
Publicado: (2009) -
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Mi Ah Han, et al.
Publicado: (2021) -
Role of the Macrophage Migration Inhibitory Factor (MIF) in the survival of first trimester human placenta under induced stress conditions
por: Francesca Ietta, et al.
Publicado: (2018) -
Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer
por: Suo N, et al.
Publicado: (2019)